Abstract:Head and neck cancer (HNC) is mainly treated by surgery, radiotherapy, and adjuvant chemotherapy; however, the prognosis of some patients with HNC is poor because of radiotherapy and chemotherapy resistance. In recent years, anti‑PD‑1 monoclonal antibodies have shown certain efficacy, and a change of the tumor immune microenvironment is the main reason for the failure of HNC immunotherapy. The present study aimed to identify and verify that CD38, which is closely related to the prognosis of HNC, is a potential biological marker of radiotherapy and chemotherapy resistance and PD-L1 immunotherapy resistance via a comprehensive bioinformatic analysis in The Cancer Genome Atlas and Gene Expression Omnibus databases. According to the UALCAN database, the transcript level of CD38 in HNC was analyzed using cluster analysis, and the expression of CD38 mRNA in HNC was detected using the Oncomine database. The characteristics of CD38-related oncogenes were identified by gene cluster enrichment analysis in LinkedOmics. The R2 and SEER databases were used to further evaluate the prognostic significance of the CD38 gene in HNC using receiver operating characteristic curve analysis of Kaplan-Meier (KM) survival and the clinical characteristics of the subjects. The protein-protein interaction network of the top 50 genes showing significant positive correlations with CD38 in HNC was analyzed using STRING. Finally, we used a nasopharyngeal carcinoma (NPC) cell line to verify the biological function. The results showed that the levels of CD38 mRNA expression in patients with HNC were significantly higher than those in healthy controls. The levels of CD38 mRNA expression in patients with HNC of different ages, sexes, and races were significantly higher than those in the healthy controls. CD38 is an independent prognostic factor for HNC, and high expression of CD38 indicates poor prognosis. CD38 expression correlated positively with the markers of many kinds of immune cells, and correlated significantly with the expression of PD-L1. We found that the high expression of CD38 suggested a poor prognosis in the subgroup of tumors treated with chemotherapeutic drugs in the G1/S phase. We used HNC cell lines to verify that the high expression of CD38 promoted the proliferation of NPC cells and produced radiotherapy tolerance. Through comprehensive bioinformatics analysis, we suggested that CD38 is a key gene involved in radiotherapy, chemotherapy, and immune drug resistance in HNC. This study provides a reliable biomarker to predict the prognosis of patients with HNC and a reference for clinical comprehensive treatment of HNC. Individualization combined with CD38 monoclonal antibodies might provide a promising treatment strategy for this fatal disease, and this comprehensive treatment might reduce the damage to normal tissue and improve the prognosis and quality of life of patients with HNC.

Integrative Analysis Identified CD38 As a Key Node That Correlates Highly with Immunophenotype, Chemoradiotherapy Resistance, And Prognosis of Head and Neck Cancer

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

CD38 Multi-Functionality in Oral Squamous Cell Carcinoma: Prognostic Implications, Immune Balance, and Immune Checkpoint.

Molecular Interplays Between Cell Invasion and Radioresistance That Lead to Poor Prognosis in Head-Neck Cancer

CD38 Expression Predicts Poor Prognosis and Might Be a Potential Therapy Target in Extranodal NK/T Cell Lymphoma, Nasal Type

Overexpression of circulating CD38+ NK cells in colorectal cancer was associated with lymph node metastasis and poor prognosis

CD38 Affects the Biological Behavior and Energy Metabolism of Nasopharyngeal Carcinoma Cells.

CD38 Identifies Pre-Activated CD8+ T Cells Which Can Be Reinvigorated by Anti-Pd-1 Blockade in Human Lung Cancer

Panoramic Analysis of Cell Death Patterns Reveals Prognostic and Immune Profiles of Head and Neck Squamous Cell Carcinoma

Unveiling NRlncRNAs as prognostic biomarkers and therapeutic targets for head‐and‐neck squamous cell carcinoma through machine learning

PD-L1 in Combination with CD8+TIL and HIF-1α are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma

Prognosis and Therapeutic Benefits Prediction Based on NK Cell Marker Genes Through Single-Cell RNA-seq with Integrated Bulk RNA-seq Analysis for Hepatocellular Carcinoma.

Bioinformatics Analysis for the Biomarkers of the Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma.

Next-generation Sequencing Identifies CDKN2A Alterations As Prognostic Biomarkers in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Predominantly Receiving Immune Checkpoint Inhibitors

Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma

Natural killer cell‐based signature: Prognostic analysis in head and neck squamous cell carcinoma

CD79A Work as a Potential Target For The Prognosis of Patients With HNSCC: Analysis of Immune Cell Infiltration In Head and Neck Squamous Cell Carcinoma Based on The CIBERSORTx Deconvolution Algorithm

879P Targeted Next-Generation Sequencing Reveals CDKN2A Alterations As a Prognostic Biomarker in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Mostly Treated with Immune Checkpoint Inhibitors

High TNF‑α And/or P38mapk Expression Predicts a Favourable Prognosis in Patients with T1N0M0 Hepatocellular Carcinoma: an Immunohistochemical Study